Table 3

Efficacy results of candidate vaccines for passive immunization against respiratory syncytial virus

Class

Vaccine structure

Clinical trial phase

Results


Human polyclonal

[77,78]

RSV IVIG

Passed clinical trials

- 40.7% relative reduction in hospitalization compared to placebo

- 63.4% relative reduction in hospitalization compared to placebo

Humanized monoclonal Ig[36]

Palivizumab

Passed clinical trials

- 54.7% relative reduction in hospitalisation compared to placebo

Humanized monoclonal Ig[37]

Motavizumab

III

- 50% relative reduction in medically attended LRI compared to Palivizumab.

- 26% relative reduction in hospitalisation compared to Palivizumab.


Nair et al. BMC Public Health 2011 11(Suppl 3):S30   doi:10.1186/1471-2458-11-S3-S30

Open Data